Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gillison

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
AJNR. American Journal of Neuroradiology|June 27, 2009
Second branchial cleft cyst: not!!P A Hudgins, M Gillison
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2022
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyA Psyrri, J Fayette, K Harrington, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
AJNR. American Journal of Neuroradiology|June 27, 2009
Second branchial cleft cyst: not!!P A Hudgins, M Gillison
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2022
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyA Psyrri, J Fayette, K Harrington, et al.
Pageof 1